Company intelligence / Profile preview

SpotitEarly

Tel Aviv, Tel Aviv, Israelspotitearly.com ↗

Ownership: Private
Development stage: Other

Overview

SpotitEarly’s at-home breath-based diagnostic platform demonstrated 94% sensitivity and specificity for early-stage detection of four major cancers in a two-year, 1,400-participant clinical trial published in Nature’s Scientific Reports. The test is non-invasive, affordable, and designed for regular home use. Additional trials are ongoing or planned as the company prepares for U.S. commercialization in 2026

Therapeutic areas: Oncology
Modalities: Device (breath collection kit)Non-pharmacological therapy (diagnostic test, not a therapeutic intervention)
Industry: Metabolite Diagnostics

Partnerships

University of Pennsylvania Science CenterTel Aviv Sourasky Medical CenterHadassah Medical CenterRambam Health Care CampusAssuta Hospital [Israel]

Beyond the preview

Go deeper on SpotitEarly.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SpotitEarly.

Explore the full profile